• ALDH2 receptor research started at Harvard
  • CVT synthesized initial compounds (2009 Gilead acquires CVT)
  • Gilead invented GS-6637 (ANS-6637), a highly selective and reversible ALDH2-inhibitor
  • Composition of matter IP thru 2032+
  • Comprehensive manufacturing process and pre-clinical development
  • Preclinical efficacy in gold standard models of addiction relapse, anxiety and binge eating
  • Clinical data from Phase-1 studies in 97 human subjects (2013-2015)
  • ANS-6637 Phase-2 Ready

ANS-6637 is a Phase-2 ready first-in-class compound that utilizes a published novel pathway for the treatment of addiction.

 

ANS-6637 is highly selective ALDH2 Inhibitor that modifies dopaminergic tone by preventing pathophysiologic dopamine surges and associated craving without changes to basal dopamine. This profile, which prevents craving and drug seeking behavior, has the potential to be used as pharmacotherapy for substance and behavior and based addictions.

MOA published in Nature Medicine

ALDH2 inhibition prevents pathophysiologic dopamine surges and associated craving without changes to basal dopamine

Dopamine surge is part of the reward circuity and common to all substance and behavioral addiction.

Addiction hijacks the reward circuit to create pathophysiologic surges​​.

DEVELOPEMENT HISTORY

ALDH2 Inhibition: Published Pre-Clinical Efficacy Data

In multiple pre-clinical models of substance abuse and anxiety, ALDH2 inhibition prevents dopamine surge without changes to basal dopamine levels, and

  • Prevents substance relapse
  • Reduces binge eating
  • Reduces anxiety

ALDH2 Inhibition: Published Neurobiologic Model of Addiction and Mechanism of Action